BioLineRx (BLRX) Begins Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer Under Immunotherapy Collaboration – StreetInsider.com
|
BioLineRx (BLRX) Begins Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer Under Immunotherapy Collaboration
StreetInsider.com The clinical study collaboration between BioLineRx and Genentech, a member of the Roche Group, is part of MORPHEUS, Roche's Novel Cancer Immunotherapy Development Platform. MORPHEUS is a phase 1b/2 adaptive platform to assess the efficacy … |
